Synmosa Biopharma (Taiwan) Today
Synmosa Biopharma is selling for under 33.40 as of the 1st of February 2025; that is 0.15% up since the beginning of the trading day. The stock's lowest day price was 33.0. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
Valuation
Check how we calculate scores
Synmosa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Synmosa Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Synmosa Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Synmosa Biopharma (4114) is traded on Taiwan OTC Exchange in Taiwan and employs 16 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 15.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Synmosa Biopharma's market, we take the total number of its shares issued and multiply it by Synmosa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Synmosa Biopharma operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 327.14 M outstanding shares.
Synmosa Biopharma has accumulated about 1.28 B in cash with 444.29 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96.
Check Synmosa Biopharma Probability Of Bankruptcy
Synmosa Biopharma Risk Profiles
Although Synmosa Biopharma's alpha and beta are two of the key measurements used to evaluate Synmosa Biopharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.7498 | |||
| Standard Deviation | 1.13 | |||
| Variance | 1.27 | |||
| Risk Adjusted Performance | (0.1) |
Synmosa Stock Against Markets
Synmosa Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Synmosa Biopharma stock to make a market-neutral strategy. Peer analysis of Synmosa Biopharma could also be used in its relative valuation, which is a method of valuing Synmosa Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Synmosa Biopharma Corporate Management
Elected by the shareholders, the Synmosa Biopharma's board of directors comprises two types of representatives: Synmosa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synmosa. The board's role is to monitor Synmosa Biopharma's management team and ensure that shareholders' interests are well served. Synmosa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synmosa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChihHui Lin | GM, Chairman | Profile | |
| Zen Young | Marketing HP | Profile | |
| Hongqin Bai | Sr Officer | Profile | |
| Banson Lin | Sr Distributors | Profile | |
| JiaXin Zhang | VP | Profile | |
| HungChin Pai | VP Officer | Profile |
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.